References
- Kuntz ID , ChenK, SharpKA, KollmanPA. The maximal affinity of ligands. Proc. Natl Acad. Sci. USA96 (18), 9997–10002 (1999).
- Hopkins Andrew L , Groom ColinR, AlexA. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today9 (10), 430–431 (2004).
- Lipinski CA . Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol.1 (4), 337–341 (2004).
- Rees DC , CongreveM, MurrayCW, CarrR. Fragment-based lead discovery. Nat. Rev. Drug Discov.3 (8), 660–672 (2004).
- Rishton GM . Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today8 (2), 86–96 (2003).
- Hopkins AL , KeseruGM, LeesonPD, ReesDC, ReynoldsCH. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov.13 (2), 105–121 (2014).
- Kenny P , LeitãoA, MontanariC. Ligand efficiency metrics considered harmful. J. Comput. Aided Mol. Des.28 (7), 699–710 (2014).
- Shultz MD . Improving the plausibility of success with inefficient metrics. ACS Med. Chem. Lett.5 (1), 2–5 (2013).
- Ligand efficiency: a response to Shultz. http://pipeline.corante.com.
- Erlanson D . In defense of ligand efficiency – and poll. http://practicalfragments.blogspot.com.
- Leeson PD , SpringthorpeB. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov.6 (11), 881–890 (2007).
- Reynolds CH , ToungeBA, BembenekSD. Ligand binding efficiency: trends, physical basis, and implications. J. Med. Chem.51 (8), 2432–2438 (2008).
- Murray CW , ErlansonDA, HopkinsALet al. Validity of ligand efficiency metrics. ACS Med. Chem. Lett.5 (6), 616–618 (2014).
- Vieth M , SutherlandJJ. Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem.49, 3451–3453 (2006).
- Nissink JW . Simple size-independent measure of ligand efficiency. J. Chem. Inf. Model.49 (6), 1617–1622 (2009).
- Zhu T , CaoS, SuP-Cet al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis: miniperspective. J. Med. Chem.56 (17), 6560–6572 (2013).
- Stamford AW , ScottJD, LiSWet al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS abeta reduction. ACS Med. Chem. Lett.3 (11), 897–902 (2012).
- Perola E . An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J. Med. Chem.53 (7), 2986–2997 (2010).